Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afalanine SCHEMBL5154381 | 0.84 | ITGB3 (0.46) | FAAHDRD2CNR1CNR2POLB | |
| SCHEMBL7683665 | 0.80 | DRD2 (0.46) | FAAHDRD2BCHEALDH1A1 | |
| SCHEMBL20898376 | 0.79 | POLB (0.43) | FAAHDRD2POLB | |
| SCHEMBL28087243 | 0.79 | POLB (0.43) | FAAHDRD2POLB | |
| Phenylalanine SCHEMBL5154392 | 0.78 | FAAH (0.49) | FAAHCNR1CNR2POLB | |
| SCHEMBL28850336 | 0.77 | FAAH (0.51) | FAAHCNR1CNR2POLB | |
| SCHEMBL28850271 | 0.76 | FAAH (0.50) | FAAHCNR1CNR2POLB | |
| SCHEMBL8583410 | 0.76 | FAAH (0.53) | FAAHDRD2ALDH1A1 | |
| SCHEMBL20898384 | 0.75 | NOS2 (0.51) | FAAHCNR1CNR2POLB | |
| SCHEMBL20900383 | 0.75 | NOS2 (0.51) | FAAHCNR1CNR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282589-B2 | Acid addition salt of optically active piperidine compound and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
| US-20040220226-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | UBE INDUSTRIES, LTD. | 2004-11-04 | — | — | US | disclosed |
| US-6780877-B2 | ANTIHISTAMINIC ACTIVITY, ANTI-ALLERGIC ACTIVITY | UBE INDUSTRIES, LTD. (JP) | 2004-08-24 | — | — | US | disclosed |
| EP-0949260-A1 | ACID-ADDITION SALTS OF OPTICALLY ACTIVE PIPERIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220226-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | DCTPP1, SSRP1, ITPA | FAAH 1684/4885DRD2 250/4885CNR1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.